 Connection
Jeffrey Kern to Lung Neoplasms
This is a "connection" page, showing publications Jeffrey Kern has written about Lung Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.492 |
|
|
|
-
Wisnivesky JP, Mudd J, Stone K, Slatore CG, Flores R, Swanson S, Blackstock W, Smith CB, Chidel M, Rosenzweig K, Henschke C, Kern JA. Longitudinal quality of life after sublobar resection and stereotactic body radiation therapy for early-stage non-small cell lung cancer. Cancer. 2024 Jul 15; 130(14):2515-2527.
Score: 0.359
-
Kern JA, Kim J, Foster DG, Mishra R, Gardner EE, Poirier JT, Rivard C, Yu H, Finigan JH, Dowlati A, Rudin CM, Tan AC. Role of mTOR As an Essential Kinase in SCLC. J Thorac Oncol. 2020 09; 15(9):1522-1534.
Score: 0.277
-
Leach SM, Finigan J, Vasu VT, Mishra R, Ghosh M, Foster D, Mason R, Kosmider B, Farias Hesson E, Kern JA. The Kinome of Human Alveolar Type II and Basal Cells, and Its Reprogramming in Lung Cancer. Am J Respir Cell Mol Biol. 2019 10; 61(4):481-491.
Score: 0.263
-
Randall TD, Kern JA. Tertiary lymphoid structures target the antitumor immune response to lung cancer. Am J Respir Crit Care Med. 2014 Apr 01; 189(7):767-9.
Score: 0.180
-
Finigan JH, Kern JA. Lung cancer screening: past, present and future. Clin Chest Med. 2013 Sep; 34(3):365-71.
Score: 0.171
-
Finigan JH, Kern JA. Lung cancer: new therapeutic targets, new definitions. Am J Respir Crit Care Med. 2012 Jul 01; 186(1):7-8.
Score: 0.159
-
Carr L, Kern JA. Computed tomography screening for lung cancer: the challenge of what and how. Am J Respir Crit Care Med. 2012 Jan 01; 185(1):8-10.
Score: 0.154
-
Carr LL, Finigan JH, Kern JA. Evaluation and treatment of patients with non-small cell lung cancer. Med Clin North Am. 2011 Nov; 95(6):1041-54.
Score: 0.152
-
Gollamudi M, Nethery D, Liu J, Kern JA. Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines. Lung Cancer. 2004 Feb; 43(2):135-43.
Score: 0.089
-
Kern JA. Sounding the mediastinum. Am J Respir Crit Care Med. 2003 Dec 01; 168(11):1261-2.
Score: 0.088
-
Wang Q, Stone K, Kern JA, Slatore CG, Swanson S, Blackstock W, Khan RS, Smith CB, Veluswamy RR, Chidel M, Wisnivesky JP. Adverse Events Following Limited Resection versus Stereotactic Body Radiation Therapy for Early Stage Lung Cancer. Ann Am Thorac Soc. 2022 12; 19(12):2053-2061.
Score: 0.082
-
Croft DR, Trapp J, Kernstine K, Kirchner P, Mullan B, Galvin J, Peterson MW, Gross T, McLennan G, Kern JA. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer. 2002 Jun; 36(3):297-301.
Score: 0.079
-
Luo J, Beattie JA, Fuentes P, Rizvi H, Egger JV, Kern JA, Leung DYM, Lacouture ME, Kris MG, Gambarin M, Santomasso BD, Faleck DM, Hellmann MD. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. J Thorac Oncol. 2021 10; 16(10):1759-1764.
Score: 0.074
-
Bruno TC, Ebner PJ, Moore BL, Squalls OG, Waugh KA, Eruslanov EB, Singhal S, Mitchell JD, Franklin WA, Merrick DT, McCarter MD, Palmer BE, Kern JA, Slansky JE. Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients. Cancer Immunol Res. 2017 10; 5(10):898-907.
Score: 0.057
-
Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics. 2014 Sep 01; 30(17):2393-8.
Score: 0.045
-
Guin S, Ru Y, Wynes MW, Mishra R, Lu X, Owens C, Barn AE, Vasu VT, Hirsch FR, Kern JA, Theodorescu D. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression. J Thorac Oncol. 2013 Dec; 8(12):1492-501.
Score: 0.044
-
Kluge A, Dabir S, Kern J, Nethery D, Halmos B, Ma P, Dowlati A. Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. Int J Cancer. 2009 Oct 01; 125(7):1728-34.
Score: 0.033
-
Yu Z, Boggon TJ, Kobayashi S, Jin C, Ma PC, Dowlati A, Kern JA, Tenen DG, Halmos B. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res. 2007 Nov 01; 67(21):10417-27.
Score: 0.029
-
Cortas T, Eisenberg R, Fu P, Kern J, Patrick L, Dowlati A. Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer. 2007 Mar; 55(3):349-55.
Score: 0.027
-
Clamon G, Herndon J, Kern J, Govindan R, Garst J, Watson D, Green M. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer. 2005 Apr 15; 103(8):1670-5.
Score: 0.024
-
D'Cunha J, Herndon JE, Herzan DL, Patterson GA, Kohman LJ, Harpole DH, Kernstine KH, Kern JA, Green MR, Maddaus MA, Kratzke RA. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung Cancer. 2005 May; 48(2):241-6.
Score: 0.024
-
Vollmer RT, Herndon JE, D'Cunha J, Abraham NZ, Solberg J, Fatourechi M, Maruska A, Kern JA, Green MR, Kratzke RA, Maddaus MA. Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761. Clin Cancer Res. 2003 Nov 15; 9(15):5630-5.
Score: 0.022
-
Liu J, Kern JA. Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. Am J Respir Cell Mol Biol. 2002 Sep; 27(3):306-13.
Score: 0.020
-
D'Cunha J, Corfits AL, Herndon JE, Kern JA, Kohman LJ, Patterson GA, Kratzke RA, Maddaus MA. Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg. 2002 Mar; 123(3):484-91; discussion 491.
Score: 0.019
-
Johnson EA, Klimstra DS, Herndon JE, Catalano E, Canellos GP, Graziano SL, Kern JA, Green MR. Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. Cancer Invest. 2002; 20(5-6):686-92.
Score: 0.019
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|